| Pharmaceutical active ingredients: |
| Cilastatin SodiumImipenem Monohydrate |
| Available forms, composition and doses of Arzomeba: |
| Injectable; Injection; Cilastatin Sodium 250 mg; Imipenem Monohydrate 250 mgInjectable; Injection; Cilastatin Sodium 500 mg; Imipenem Monohydrate 500 mg |
| Arzomeba medical category: |
| Human:Beta-LactamsCarbapenems |
| Indications and usages, anatomical therapeutic chemical and diseases classification codes: |
| J01DH51 - Imipenem and enzyme Inhibitor |
| Pharmaceutical companies: manufacturers, researchers, developers, local distributors and suppliers: |
| Pisa Laboratorios |
| Trade name |
Active ingredients |
Pharmaceutical company |
|
Ran-Imipenem-Cilastatin | Cilastatin Sodium; Imipenem | Ranbaxy |
| Tenacid | Cilastatin Sodium; Imipenem | Sigma-Tau Pharmaceuticals |
| Timipen | Cilastatin Sodium; Imipenem | Interbat |
| Tracix | Cilastatin Sodium; Imipenem | Merck |
| Zienam | Cilastatin Sodium; Imipenem | Merck |
| Cilastatin; Imipenem | Cilastatin Sodium; Imipenem Monohydrate | Mylan |
| Lemibet | Cilastatin Sodium; Imipenem Monohydrate | Teva |
| Lemibet I.M. | Cilastatin Sodium; Imipenem Monohydrate | Teva |
| Lemibet I.V. | Cilastatin Sodium; Imipenem Monohydrate | Teva |
| Tienam | Cilastatin Sodium; Imipenem Monohydrate | Merck; BLH Trading; Neopharmed; Zuellig Pharma |